[go: up one dir, main page]

UY30986A1 - Derivados fluorinados de deferiprona - Google Patents

Derivados fluorinados de deferiprona

Info

Publication number
UY30986A1
UY30986A1 UY30986A UY30986A UY30986A1 UY 30986 A1 UY30986 A1 UY 30986A1 UY 30986 A UY30986 A UY 30986A UY 30986 A UY30986 A UY 30986A UY 30986 A1 UY30986 A1 UY 30986A1
Authority
UY
Uruguay
Prior art keywords
deferiprone
derivatives
fluorinated
iron
relates
Prior art date
Application number
UY30986A
Other languages
English (en)
Inventor
Zhao Yanqing
Wang Yingsheng
Leung-Toung Regis
Tam Tim Fat
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of UY30986A1 publication Critical patent/UY30986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con derivados novedosos de deferiprona. En particular, la presente invencion se relaciona con derivados de deferiprona o sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas que comprenden los mismos, procesos para la manufactura de los mismos y su uso en el tratamiento de enfermedades neurodegenerativas causadas por la presencia de hierro libre o acumulacion de hierro en tejidos neuronales y en enfermedades donde el exceso de hierro debe ser removido o redistribuido.
UY30986A 2007-03-28 2008-03-27 Derivados fluorinados de deferiprona UY30986A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90729007P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
UY30986A1 true UY30986A1 (es) 2008-09-02

Family

ID=39743019

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30986A UY30986A1 (es) 2007-03-28 2008-03-27 Derivados fluorinados de deferiprona

Country Status (15)

Country Link
US (2) US8026261B2 (es)
EP (1) EP2134688B1 (es)
CN (2) CN101679263B (es)
AR (1) AR065880A1 (es)
AU (1) AU2008232262B2 (es)
CA (2) CA2681545C (es)
CL (1) CL2008000887A1 (es)
IL (1) IL201189A (es)
MX (1) MX2009010407A (es)
NZ (2) NZ600874A (es)
PE (1) PE20081596A1 (es)
TW (1) TWI404533B (es)
UY (1) UY30986A1 (es)
WO (1) WO2008116301A1 (es)
ZA (1) ZA200906712B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600874A (en) 2007-03-28 2013-01-25 Apotex Technologies Inc Fluorinated derivatives of deferiprone
GB0803019D0 (en) * 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
AP2010005454A0 (en) 2008-04-25 2010-12-31 Apotex Technologies Inc Liquid formulation for deferiprone with palatable taste.
CN102712591B (zh) * 2009-07-03 2014-06-25 阿普泰克斯科技公司 3-羟基吡啶-4-酮的氟化衍生物
ES2542431T3 (es) 2010-11-29 2015-08-05 Pfizer Inc Monobactamas
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013073577A1 (ja) 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
US10802459B2 (en) 2015-04-27 2020-10-13 Ademco Inc. Geo-fencing with advanced intelligent recovery
US10516965B2 (en) 2015-11-11 2019-12-24 Ademco Inc. HVAC control using geofencing
US10605472B2 (en) 2016-02-19 2020-03-31 Ademco Inc. Multiple adaptive geo-fences for a building
WO2017152237A1 (en) * 2016-03-10 2017-09-14 The University Of Sydney Novel analogues of desferrioxamine b (dfob)
CN111170936B (zh) * 2020-01-19 2021-01-01 杭州泽德医药科技有限公司 3,4-二羟基-n-(1’-苄基-2’-羟乙基)-2-甲基吡啶氯化物及制备和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) * 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
BE639493A (es) 1962-12-20
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
USRE34313E (en) 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
DE3826846A1 (de) 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
EP0620001A1 (en) 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
NZ276786A (en) 1994-01-31 1998-05-27 Cultor Corp Synthesis of gamma-pyrones from a haloenone intermediate
JP2001508755A (ja) 1994-04-08 2001-07-03 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳動物でラジカルダメージを減少させるために鉄キレート化合物を用いる方法
AU3154895A (en) 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
WO2000012135A1 (fr) 1998-08-28 2000-03-09 Eisai Co., Ltd Compositions medicales presentant une amertume, etc., reduite
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2004535370A (ja) 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
AU2003222513A1 (en) 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
EP1482789A4 (en) 2002-03-12 2010-12-29 Toyama Chemical Company Ltd TASTY ORAL SUSPENSION AND METHOD
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
WO2004041151A2 (en) 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
DE10336497B4 (de) * 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
EP1742535A4 (en) 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
CA2568134A1 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
JP2006150061A (ja) 2004-11-04 2006-06-15 Nec Corp ドラッグデリバリシステム及びそれに用いる薬剤カプセル並びに送信機
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
CA2642778A1 (en) 2006-02-22 2007-08-30 Arnold Munnich The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
NZ600874A (en) 2007-03-28 2013-01-25 Apotex Technologies Inc Fluorinated derivatives of deferiprone
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
CL2008000887A1 (es) 2008-05-30
EP2134688A1 (en) 2009-12-23
CN102964296B (zh) 2015-03-25
NZ600874A (en) 2013-01-25
AR065880A1 (es) 2009-07-08
MX2009010407A (es) 2009-12-01
US20120095061A1 (en) 2012-04-19
TWI404533B (zh) 2013-08-11
CN101679263A (zh) 2010-03-24
IL201189A0 (en) 2010-05-17
US20080242706A1 (en) 2008-10-02
ZA200906712B (en) 2011-02-23
CA2681545A1 (en) 2008-10-02
US8026261B2 (en) 2011-09-27
EP2134688B1 (en) 2016-10-05
NZ579928A (en) 2012-09-28
PE20081596A1 (es) 2009-02-05
AU2008232262A1 (en) 2008-10-02
WO2008116301A1 (en) 2008-10-02
AU2008232262B2 (en) 2013-02-14
CN101679263B (zh) 2014-01-15
TW200843760A (en) 2008-11-16
IL201189A (en) 2015-06-30
CA2627529A1 (en) 2008-09-28
EP2134688A4 (en) 2011-01-19
CN102964296A (zh) 2013-03-13
US8673943B2 (en) 2014-03-18
CA2681545C (en) 2013-10-01

Similar Documents

Publication Publication Date Title
UY30986A1 (es) Derivados fluorinados de deferiprona
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CR9475A (es) Derivados de amina substituidos como inhibidores de proteina kinasa
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
UY33616A (es) Compuestos con estructura de imidazotriazinona
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
UY32622A (es) Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
UY31922A (es) Compuestos
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
GT200500360A (es) Compuestos organicos
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191008